home.social

#adcplatform — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #adcplatform, aggregated by home.social.

  1. Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
    #YonhapInfomax
    #SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
    #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

  2. Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
    #YonhapInfomax
    #SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
    #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

  3. Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
    #YonhapInfomax
    #SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
    #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

  4. Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
    #YonhapInfomax
    #SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
    #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV